

## Clinical Policy: Thyrotropin Alfa (Thyrogen)

Reference Number: LA.PHAR.95

Effective Date: 10.30.22

Last Review Date: ~~02.06.2504.18.24~~

Line of Business: Medicaid

[Coding Implications](#)  
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Thyrotropin alfa (Thyrogen<sup>®</sup>) is a recombinant human thyroid stimulating hormone (TSH).

### FDA Approved Indication(s)

Thyrogen is indicated for:

- Diagnostic: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.
- Ablation: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitation(s) of use:

- Diagnostic:
  - Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with, Tg levels after thyroid hormone withdrawal.
  - Even when Thyrogen-stimulated Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or of underestimating the extent of disease.
  - Anti-Tg antibodies may confound the Tg assay and render Tg levels uninterpretable.
- Ablation: The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections that Thyrogen is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Thyroid Cancer (must meet all):

1. Diagnosis of well-differentiated thyroid cancer;
2. Age  $\geq$  18 years;
3. Thyrogen will be used for one of the following (a or b):

**CLINICAL POLICY**  
Thyrotropin Alfa



- a. Adjunctive treatment for radioiodine ablation of thyroid tissue remnants and both of the following are met (i and ii):
    - i. Member has undergone a near-total or total thyroidectomy;
    - ii. There is no evidence of distant metastatic thyroid cancer;
  - b. Adjunctive diagnostic tool for serum Tg testing in members who have previously undergone thyroidectomy;
4. Dose does not exceed an initial 0.9 mg IM injection followed by a second 0.9 mg IM injection 24 hours later.

**Approval duration: 6 months (2 injections)**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 ~~for Medicaid~~.

**II. Continued Therapy**

**A. Thyroid Cancer** (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Thyrogen will be used as an adjunctive diagnostic tool for serum Tg testing;
4. If request is for a dose increase, new dose does not exceed an initial 0.9 mg IM injection followed by a second 0.9 mg IM injection 24 hours later.

**Approval duration: 6 months (2 injections)**

**B. Other diagnoses/indications** (1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 ~~for Medicaid~~.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 ~~for Medicaid, or evidence of coverage documents~~.

Formatted: Font: Bold

**CLINICAL POLICY**  
Thyrotropin Alfa



**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration  
IM: intramuscular

Tg: thyroglobulin  
TSH: thyroid stimulating hormone

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): If Thyrogen is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen.
- Boxed warning(s): none reported.

**V. Dosage and Administration**

| Indication   | Dosing Regimen  | Maximum Dose |
|--|---|--------------|
| Adjunctive diagnostic tool for serum thyroglobulin testing in well-differentiated thyroid cancer | 0.9 mg IM injection to the buttock followed by a second 0.9 mg IM injection to the buttock 24 hours later | See regimen  |
| Adjunct to treatment for ablation in well-differentiated thyroid cancer                          |   |              |

**VI. Product Availability**

Single-dose vial lyophilized powder: 0.9 mg

**VII. References**

1. Thyrogen Prescribing Information. Cambridge, MA: Genzyme Corporation; ~~March 2020~~ February 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/020898s063s0651bl.pdf.thyroge n.com/](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020898s063s0651bl.pdf.thyroge n.com/). Accessed ~~April 25, 2023~~ May 13, 2024.
2. National Comprehensive Cancer Network. Thyroid Carcinoma Version ~~1.2023~~ 2024. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed ~~April 25, 2023~~ May 29, 2024.

Formatted: Indent: Hanging: 0.31", No page break before

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description   |
|-------------|---|
| J3240       | Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial |

Formatted: Font: Bold

**CLINICAL POLICY**  
Thyrotropin Alfa



Formatted: Font color: Text 2  
Formatted: Normal

| Reviews, Revisions, and Approvals  | Date            | LDH Approval Date |
|--|-----------------|-------------------|
| Converted corporate to local policy.   | 09.22           | 10.30.22          |
| Template changes applied to other diagnoses/indications and continued therapy section. Internal hyperlinks updated and references reviewed and updated.<br>Added blurb this policy is for medical benefit only | 06.13.23        | 10.05.23          |
| Annual review: no significant changes; references reviewed and updated.  | 04.18.24        | <u>07.10.24</u>   |
| <u>Annual review: no significant changes; references reviewed and updated.</u>   | <u>02.06.25</u> |                   |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

**CLINICAL POLICY**  
Thyrotropin Alfa



Formatted: Font color: Text 2  
Formatted: Normal

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.

Formatted: Indent: Left: 0", Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers  
Formatted: Indent: Left: 0"